Últimas noticias sobre Polar Power (NASDAQ:POLA) Bolsa

Polar Power

Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.

Polar Power Inc

POLAR CAP GLOBAL FNCL TR by POLAR CAP GLOBAL FINANCIALS TR PLC

POLAR CAPITAL TECH TR NEW by Polar Capital Technology Trust Plc.

POLAR CAPITAL TECH TR PLC by Polar Capital Technology Trust Plc.

POLAR PETROLEUM CORP by Polar Petroleum Corp.

POLA ORBIS HOLDINGS INC by Pola Orbis Holdings Inc

Pola Orbis Holdings Inc

POLAR CAPITAL HOLDING ORD by Polar Capital Holdings PLC

Polar Capital Holdings PLC

PolarX Ltd

POLAREAN IMAGING LTD by Polarean Imaging Ltd.

Polarean Imaging PLC

POLARIS HLDGS CO LTD by POLARIS HLDGS CO LTD

Polaris Holdings Co Ltd

Polaris Inc

POLARIS INTL HOLDINGS INC by Polaris International Holdings, Inc.

Polaris International Holdings Inc

Polaris Northstar Capital Corp

POLARIS NORTHSTAR CAP CRP by POLARIS NORTHSTAR CAP CORP.

POLARIS RENEWABLE ENERGY by POLARIS RENEWABLE ENERGY INC.

Polaris Renewable Energy Inc

PolarityTE Inc

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and lowers the price target from $362 to $351.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Molina Healthcare, Lowers Price Target to $351

Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) on Monday announced its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45719054/guardian-pharmacy-services-expands-pacific-northwest-footprint-with-acquisition-of-washington-base" rel="noreferrer noopener">entry into the Pacific Northwest market</a> through the acquisition of Mercury Pharmacy Services, a Mountlake Terrace-based provider of long-term care (LTC) pharmacy solutions.
The move strengthens Guardian's national presence and addresses the growing demand for LTC support in Washington state, the company said in a press release.
The financial terms of the deal, one of Guardian&#8217;s larger recent single-pharmacy acquisitions, were not disclosed.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data" rel="noreferrer noopener">Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data</a>
The deal brings a well-established operation serving assisted living, skilled nursing, behavioral health, and disability care communities across the Seattle-Tacoma region.
Fred Burke, Guardian's CEO, said the company seeks high-performing local partners in regions with unmet needs. He highlighted Mercury's strong market reputation as a natural fit for Guardian's expansion goals.
Mercury, founded in 2001, will retain its name and staff, continuing operations under Guardian's ownership. The company will also gain access to Guardian's centralized resources, including IT, analytics, and HR support, enabling its team to focus on patient care and service delivery.
Founded in 2004, Guardian now operates over 50 pharmacies serving more than 7,000 LTC facilities nationwide, growing through a mix of acquisitions, startups, and organic development.
GRDN held <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45359262/guardian-pharmacy-services-inc-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">cash and cash equivalents</a> of $14 million as of March 31, 2025.
Related ETFs: Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>), iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>).
Price Action: GRDN shares closed lower by 1.03% at $21.17 on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout" target="_blank" rel="noreferrer noopener">Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout</a></li>
</ul>
Image via Shutterstock

Movers

GRDN

iShares Trust Dow Jones US Healthcare Sector Index Fund

Guardian Pharmacy Strengthens US Footprint With New Seattle-Area Acquisition

<a href="https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/" title="https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/">https://capitolnewsillinois.com/news/new-taxes-on-sports-bets-nicotine-products-as-democrats-pass-55-2b-budget/</a>

CHDN

DKNG

FLUT

GAMB

PENN

WYNN

Reported June 1, 2025: 'New Taxes On Sports Bets, Nicotine Products As Democrats Pass $55.2B Budget' - Capital News Illinois

Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) stock is trading lower on Monday after reporting <a href="https://www.benzinga.com/pressreleases/25/06/g45717713/saic-announces-first-quarter-of-fiscal-year-2026-results">the first-quarter 2026 earnings</a>.
The company reported&nbsp;quarterly sales growth&nbsp;of 2% year-on-year to $1.88 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $1.87 billion.
The adjusted EPS of $1.92&nbsp;missed the analyst consensus&nbsp;estimate of $2.22.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/45720002/campbells-brews-up-strong-q3-beats-estimates-as-home-cooking-sector-simmers">Campbell&#8217;s Brews Up Strong Q3: Beats Estimates As Home Cooking Sector Simmers</a>
Operating income for the quarter declined by 8% to $121 million, and the operating margin declined by 70 basis points to 6.4%.
Adjusted EBITDA decreased 5% to $157 million with an adjusted EBITDA margin of 8.4%, a 60 basis points decline.
Net bookings for the quarter were approximately $2.4 billion, which reflects a book-to-bill ratio of 1.3.&nbsp;
The quarter&#8217;s operating cash flow totaled $100 million. Free cash flow was an outflow of $44 million.
SAIC&#8217;s estimated backlog for the quarter was approximately $22.3 billion, of which $3.3 billion was funded. As of May 2, 2025, the company held $47 million in cash and equivalents.
CEO Toni Townes-Whitley acknowledged the steady progress it made against its enterprise growth strategy despite a still dynamic operating environment.
Science Applications <a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">reiterated the 2026</a> revenue outlook of $7.60 billion-$7.75 billion, below the analyst consensus estimate of $7.93 billion.
The company maintained an annual adjusted EPS outlook of $9.10-$9.30 below the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a> of $10.24.
Price Action: SAIC shares are trading lower by 10.7% to $103.21 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45716922/taiwan-semiconductor-eyes-uae-gigafab-seeks-crucial-us-green-light" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Eyes UAE Gigafab, Seeks Crucial US Green Light</a></li>
</ul>
Photo by DCStockPhotography via Shutterstock

Earnings

Guidance

Tech

SAIC

SAIC Stock Falls After Q1 Earnings Miss, Soft Guidance

Rivian Automotive, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) stock traded lower Monday by about 2.86% after the electric vehicle company announced plans to offer $1.25 billion in senior secured green notes due 2031 in <a href="https://www.benzinga.com/pressreleases/25/06/b45717976/rivian-automotive-inc-announces-proposed-1-25-billion-senior-secured-green-notes-offering-to-refin" target="_blank" rel="noreferrer noopener">a private offering</a>.
The EV manufacturer plans to use the offering proceeds and cash on hand to redeem $1.25 billion of outstanding floating rate senior secured notes due 2026 and pay related fees and expenses.
Rivian held $7.2 billion in <a href="https://www.benzinga.com/pressreleases/25/05/b45235082/rivian-releases-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">cash and equivalents</a> as of March 31.
Also Read: <a href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration" target="_blank" rel="noreferrer noopener">This Tesla Rival Taps AI Expert Aidan Gomez To Drive Innovation</a>
Riavian stock is up close to 10% year-to-date and over 27% in the last 12 months.
Rivian had a better-than-expected <a target="_blank" href="https://www.benzinga.com/25/05/45642153/rivian-ceo-rj-scaringe-touts-45000-rivian-r2s-updated-rear-suspension-cant-wait-for-folks" rel="noreferrer noopener">first quarter 2025</a>, reporting quarterly revenue of $1.24 billion, a 3% increase. However, Rivian&nbsp;slashed its delivery projections&nbsp;for 2025 amid tariff uncertainty, which could raise the company&#8217;s cost per vehicle.
Rivian CEO RJ Scaringe had <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45617151/ubs-maintains-neutral-rating-for-rivian-stock-sets-price-13-price-target" target="_blank" rel="noreferrer noopener">voiced the company&#8217;s</a> plans for the R2, which is seen as an affordable option in Rivian&#8217;s otherwise costly line-up of SUVs and Pickup trucks.
The car maker also expanded its facility in Normal, Illinois, with a $120 million investment, which could create hundreds of jobs as the company reaffirmed its U.S.-centric supply chain.
CNBC&#8217;s Jim Cramer&nbsp;said&nbsp;Rivian <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45562808/jim-cramer-rivian-better-than-this-automaker-pan-american-silver-is-the-best-silver-mine" target="_blank" rel="noreferrer noopener">is better than</a>&nbsp;Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>).
Price Action: Rivian shares are trading lower at aruond $14.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45717955/chinas-nio-clocks-13-deliveries-growth-in-may-tesla-lags" target="_blank" rel="noreferrer noopener">China&#8217;s NIO Clocks 13% Deliveries Growth In May, Tesla Lags</a></li>
</ul>
Image: Shutterstock

Bonds

Offerings

LCID

RIVN

Rivian Stock Goes Red After Offering $1.25 Billion Green Bond To Refinance 2026 Debt

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $322 to $273.

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $273

VivoPower to leverage BitGo's best-in-class OTC trading desk and custody platform to build digital asset treasury strategy
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- BitGo, the leading infrastructure provider of digital asset solutions, and VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, "VivoPower"))), a publicly traded company that recently announced transition to an XRP focused treasury and decentralized finance solutions company, today announced a strategic partnership. VivoPower, having successfully raised US$121 million, will leverage BitGo as an exclusive over-the-counter (OTC) trading desk to acquire XRP for its initial US$100 million acquisition of XRP tokens.
VivoPower will exclusively leverage BitGo for both the trading of its XRP holdings through BitGo's 24/7/365 OTC trading desk and holding of its assets through BitGo's best-in-class custody platform. As a result, VivoPower is expected to benefit from BitGo's liquidity, robust execution capabilities, and secure cold storage infrastructure.

VVPR

VivoPower Forms Strategic Partnership With BitGo To Launch $100M XRP Acquisition And Digital Asset Treasury Strategy Using BitGo's Premier OTC Trading Desk and Custody Platform

Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and raises the price target from $366 to $416.

Barclays Maintains Overweight on HCA Healthcare, Raises Price Target to $416

<a href="https://www.dallasfed.org/banking/events/2025/25banking">https://www.dallasfed.org/banking/events/2025/25banking</a>
&nbsp;
&nbsp;

Macro Economic Events

Economics

Federal Reserve

Fed's Logan Says Despite Uncertainty, Financial Market Volatility, Us Economy Is Resilient; Labor Market Is Stable; Inflation Still Somewhat Above Target; Risks Are Balanced On Both Sides Of Mandate; If Tariffs Change Inflation Expectations That Would Be Significant; Market Volatility, Uncertainty Could Cause Households, Businesses To Pull Back; Monetary Policy Well Positioned To Wait, Be Patient; Well-Positioned To Act If Risks Materialize

Uranium Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year.

Uranium Energy Q3 EPS $(0.07) Down From $(0.05) YoY

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $522 to $480.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $480

Rumors

Trading Ideas

Watching V.F. Corporation; Hearing Popular Newsletter Picks Stock

Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Overweight and raises the price target from $14 to $22.

REPL

Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $22

<a href="https://www.nbcnews.com/politics/supreme-court/supreme-court-denies-challenges-state-laws-banning-assault-style-weapo-rcna187702">https://www.nbcnews.com/politics/supreme-court/supreme-court-denies-challenges-state-laws-banning-assault-style-weapo-rcna187702</a>
&nbsp;

SWBI

'Supreme Court Won't Hear Challenge To Maryland Assault Weapons Ban' - NBC News

Barclays analyst Andrew Mok maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and lowers the price target from $82 to $79.

Barclays Maintains Overweight on CVS Health, Lowers Price Target to $79

U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points on Monday.
Following the market opening Monday, the Dow traded down 0.72% to 41,967.43 while the NASDAQ fell 0.38% to 19,040.92. The S&amp;P 500 also fell, dropping, 0.58% to 5,877.58.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, real estate stocks fell by 1.5%.
Top Headline
The Campbell&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) posted better-than-expected third-quarter results on Monday.
The company reported third-quarter sales growth of 4% year over year (Y/Y) to $2.475 billion, beating the analyst consensus estimate of $2.43 billion. Adjusted EPS of $0.73 beat the consensus estimate of $0.66.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares shot up 486% to $28.90 after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.</li>
<li>Shares of InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) got a boost, surging 194% to $7.31.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) shares were also up, gaining 113% to $0.2455. Oragenics recently announced a 1-for-30 reverse stock split.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares dropped 31% to $5.64.</li>
<li>Shares of SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) were down 34% to $50.45 after the company announced a mixed-shelf offering</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) was down, falling 30% to $0.7457 after the company announced it commenced a public offering of pre-funded warrants.</li>
</ul>
Commodities In commodity news, oil traded up 3.1% to $62.67 while gold traded up 2.5% at $3,398.50.
Silver traded up 3.9% to $34.330 on Monday, while copper rose 4.5% to $4.8865.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.6%, while Spain's IBEX 35 Index fell 0.3%. London's FTSE 100 fell 0.3%, Germany's DAX 40 dipped 0.8% and France's CAC 40 fell 0.7% during the session.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei falling 1.30%, Hong Kong's Hang Seng Index dipping 0.57% and India's BSE Sensex declining 0.1%.
Economics
<ul class="wp-block-list">
<li>The ISM Manufacturing PMI declined to 48.5 in May compared to 48.7 in April, also missing market estimates of 49.5.</li>
<li>U.S. construction spending declined by 0.4% month-over-month to an annual rate of $2,152.4 billion in April following a revised 0.8% fall in March.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to a reading of 52 in May versus a preliminary reading of 52.3.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Markets

LYRA

MULN

OGEN

SBET

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Alliance Global Partners analyst Matthew Venezia initiates coverage on Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) with a Buy rating and announces Price Target of $12.

Initiation

PLUR

Alliance Global Partners Initiates Coverage On Pluri with Buy Rating, Announces Price Target of $12

General

PATH

HCLTech and UiPath Announce Strategic Partnership To Drive Large-Scale Transformation For Enterprises Across Industries

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 5 years by 4.07% on an annualized basis producing an average annual return of 17.0%. Currently, Travelers Companies has a market capitalization of $61.76 billion. 
Buying $100 In TRV: If an investor had bought $100 of TRV stock 5 years ago, it would be worth $231.02 today based on a price of $272.60 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748873713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Travelers Companies 5 Years Ago Would Be Worth This Much Today

BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) and Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a href="https://www.benzinga.com/pressreleases/25/06/b45717442/biontech-and-bristol-myers-squibb-announce-global-strategic-partnership-to-co-develop-and-co-comme" target="_blank" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech&#8217;s investigational bispecific antibody BNT327 across numerous <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">solid tumor types</a>.
Under the agreement, BioNTech and Bristol Myers Squibb will work jointly to broaden and accelerate the development of this clinical candidate.
Also Read: <a href="https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion" target="_blank" rel="noreferrer noopener">BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion</a>
BioNTech&#8217;s BNT327 is currently under extensive evaluation in multiple ongoing clinical trials, with over 1,000 patients having received the treatment to date. 
These evaluations include global Phase 3 trials with registrational potential, investigating BNT327 as a first-line treatment for both extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). 
Furthermore, BioNTech plans to initiate an additional global Phase 3 trial by the end of 2025 to assess the candidate&#8217;s efficacy in treating triple-negative breast cancer (TNBC).
Under the terms of the agreement, the companies will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. 
Both companies have the right to independently develop BNT327 in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets.
Bristol Myers Squibb will pay BioNTech $1.5 billion in an upfront payment and $2 billion in non-contingent anniversary payments through 2028.
These tax-deductible charges will be recorded as Acquired IPR&amp;D Expense when incurred, with the $1.5 billion being incurred in Q2.
In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
BioNTech and Bristol Myers Squibb will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions. Global profits/losses will be equally shared between BioNTech and Bristol-Myers Squibb.
In May, Bristol-Myers Squibb agreed to pay $350 million to the State of Hawaii to settle claims related to the prescription drug Plavix, an antiplatelet drug that prevents blood clots by keeping platelets in the blood from coming&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit" rel="noreferrer noopener">together and making clots</a>.
The agreement resolves a lawsuit filed by the state that alleged the pharmaceutical company engaged in deceptive practices surrounding the development, labeling, and marketing of the drug.
Price Action: BNTX stock is trading higher by 14.8% to $109.95, and BMY stock is trading lower by 0.62% to $47.98 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asset-sales/25/06/45721138/dow-exits-dowaksa-jv-stays-course-on-best-owner-strategy" target="_blank" rel="noreferrer noopener">Dow Exits DowAksa JV, Stays Course On &#8216;Best-Owner&#8217; Strategy</a></li>
</ul>
Photo via Shutterstock

Comments

Polar Power

Noticias

Últimas noticias sobre Polar Power (NASDAQ:POLA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL